Semaglutide is a GLP-1 receptor agonist that suppresses appetite and reduces body weight. It is FDA-approved for weight management and type 2 diabetes.
Mimics GLP-1, reducing gastric emptying, suppressing glucagon, and acting on hypothalamic appetite centres to reduce caloric intake.
Nausea, vomiting, diarrhoea, and constipation, especially during dose escalation. Rare: pancreatitis.
Start at 0.25 mg/week. Escalate by 0.25 mg every 4 weeks to a maximum of 2.4 mg/week.